SCHEMBL3347533

SCHEMBL3347533

NC(=O)c1ccc(-c2c[nH]c3ncc(F)cc23)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 2/20 0.46
CLK1 P49759 5/20 0.42
AKT1 P31749 1/20 0.42
DYRK1A Q13627 5/20 0.42
AXL P30530 2/20 0.42
GSK3A P49840 2/20 0.42
GSK3B P49841 2/20 0.42
CLK2 P49760 2/20 0.42
CLK4 Q9HAZ1 2/20 0.42
CDK2 P24941 2/20 0.42
CDC7 O00311 1/20 0.42
PLK4 O00444 1/20 0.42
CHEK1 O14757 1/20 0.42
AURKA O14965 1/20 0.42
MAPK13 O15264 1/20 0.42
PDPK1 O15530 1/20 0.42
DYRK3 O43781 1/20 0.42
ROCK2 O75116 1/20 0.42
RPS6KA5 O75582 1/20 0.42
PRKD3 O94806 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3348398 0.85 JAK2 (0.50) MAP3K11CLK1AKT1DYRK1AAXL
SCHEMBL3353465 0.83 MAP3K11 (0.47) MAP3K11CLK1AKT1DYRK1AAXL
SCHEMBL4376699 0.79 AKT1 (0.63) AKT1DYRK1AGSK3BCLK2CLK4
SCHEMBL3347541 0.78 CLK1 (0.42) MAP3K11CLK1DYRK1ACLK2CLK4
SCHEMBL22946828 0.76 GSK3A (0.38) GSK3AGSK3B
SCHEMBL3349917 0.74 AKT1 (0.44) MAP3K11AKT1DYRK1AAXLGSK3A
SCHEMBL22049462 0.73 AXL (0.42) MAP3K11CLK1DYRK1AAXLGSK3A
SCHEMBL24630092 0.71 AAK1 (0.46) CLK1DYRK1AAXLGSK3AGSK3B
SCHEMBL12663473 0.71 SGK1 (0.65) DYRK1AAXLGSK3AGSK3BCLK2
SCHEMBL28904824 0.70 KDM4E (0.41) MAP3K11CLK1DYRK1AAXLGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180370966-A1 METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2018-12-27 US disclosed
US-9873693-B2 Methods of treatment using pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-01-23 US disclosed
US-8778977-B2 Pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2014-07-15 US disclosed
EP-2038272-B1 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHARMACEUTICALS INC (US) 2013-09-04 EP disclosed
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHAMACEUTICALS (US) 2010-06-10 US disclosed
EP-2038272-A2 PYRIDINONYL PDK1 INHIBITORS Sunesis Pharmaceuticals, Inc. (US) 2009-03-25 EP disclosed
WO-2008005457-A2 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHARMACEUTICALS (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180370966-A1 METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS PDK1, PDK2, PDK3 MAP3K11 139/4885CLK1 493/4885AKT1 318/4885
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS PDK1, PDK2, PDK3 MAP3K11 95/4885CLK1 472/4885AKT1 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.